The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has unveiled plans to evaluate the safety and efficacy of futibatinib (TAS-120), a potent inhibitor of the fibroblast growth factor receptor (FGFR).

The oncology research programme of NCCN provides innovation and knowledge discovery that can improve the lives of cancer patients. It also supports preclinical, clinical research and quality improvement projects in the field of oncology at member institutions of NCCN.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the project, NCCN will evaluate pre-clinical, translational and clinical trials using futibatinib as a monotherapy and in biologically relevant combination regimens for malignancies identified with FGFR 1-4 aberrations.

This research project will be the first NCCN programme to assess the efficacy of an FGFR inhibitor.

NCCN chief medical officer Wui-Jin Koh said: “We still have a lot to learn about FGFR signalling and how to optimally target this receptor as a component of cancer therapy. We look forward to the potential new discoveries that may come from these investigations.”

The research project is backed by $2m in funding from Japanese pharmaceutical firm Taiho Oncology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Taiho Oncology senior vice-president and chief medical officer Martin J Birkhofer said: “We are proud to support NCCN ORP research to better understand the optimal role of futibatinib in treating malignancies with FGFR 1-4 aberrations.

“Every day, we are learning more and more about futibatinib, and this research will expand our knowledge of how this investigational compound works, with the goal of being able to better target its use in those who may see the greatest benefit from it.”

NCCN noted that the first phase of this research project will involve the RFP creation, which is expected to be distributed in the coming months.

The awarded projects under the ORP will be revealed after the review of submitted proposals.